Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Oncotarget - 1 May 2013

Gillis Joanna L, Selth Luke A, Centenera Margaret M, Townley Scott L, Sun Shihua, Plymate Stephen R, Tilley Wayne D, Butler Lisa M

Abstract excerpt

The development of lethal, castration resistant prostate cancer is associated with adaptive changes to the androgen receptor (AR), including the emergence of mutant receptors and truncated, constitutively active AR variants. AR relies on the molecular chaperone HSP90 for its function in both normal and malignant prostate cells, but the requirement for HSP90 in environments with aberrant AR expression is largely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Isoxazoles

Share to Lactams, Macrocyclic

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Transcription, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 23674566
DOI: 10.18632/oncotarget.975
PMCID: PMC3742830

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.PMID 23674566Read ↗

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsSemantic proximity Read ↗

Hsp90 as a therapeutic target in prostate cancer.Semantic proximity Read ↗

Decoding the androgen receptor splice variants.Semantic proximity Read ↗

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Semantic proximity Read ↗

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.Semantic proximity Read ↗

AR Splicing Variants and Resistance to AR Targeting AgentsSemantic proximity Read ↗

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variantSemantic proximity Read ↗

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerSemantic proximity Read ↗

<scp>Androgen receptor</scp> splice variant 7 in castration‐resistant prostate cancer: Clinical considerationsSemantic proximity Read ↗

Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancerSemantic proximity Read ↗

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptorSemantic proximity Read ↗

Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization SignalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.